Childhood Acute Megakaryocytic Leukemia (M7) Clinical Trial
Official title:
Observational - NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia
This laboratory study is looking into genes in samples from younger patients with acute megakaryoblastic leukemia (AMKL). Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and identify biomarkers related to cancer
Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective:
Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Cryopreserved
mRNA Study Population Description: Samples from AAML0531 Sampling Method: Non-Probability
Sample
OBJECTIVES:
I. To determine whether NUP98/JARID1A expression is a recurrent translocation in
NUP98-rearranged cases in pediatric acute megakaryoblastic leukemia (AMKL).
II. To screen the Children Oncology Group (COG) samples for genetic aberrations in pediatric
AMKL.
OUTLINE:
Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1,
myeloid/lymphoid or mixed-lineage leukemia (MLL)-rearrangements, and other gene expression
profiling by reverse transcriptase polymerase chain reaction (RT-PCR) and karyotyping or
fluorescence in situ hybridization (FISH). Results are then compared with each patient's
outcome data.
;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01427881 -
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
| Recruiting |
NCT01146210 -
Identification of de Novo Fanconi Anemia in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
|
N/A | |
| Terminated |
NCT00096148 -
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
Phase 2 | |
| Completed |
NCT00006363 -
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
|
Phase 3 | |
| Terminated |
NCT01801046 -
Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia
|
Phase 1 | |
| Completed |
NCT01076569 -
Biomarkers in Bone Marrow Samples From Pediatric Patients With High-Risk Acute Myeloid Leukemia
|
N/A | |
| Completed |
NCT00369317 -
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
|
Phase 3 | |
| Completed |
NCT01177371 -
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
|
Phase 2 | |
| Completed |
NCT00002798 -
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
|
Phase 3 | |
| Completed |
NCT00666588 -
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia
|
Phase 2 |